Longeveron (LGVN) shares experienced a significant rise due to a recent $30 million private placement funding their lead candidate, laromestrocel. With an upcoming and critical Phase 2b ELPIS II trial data readout for Hypoplastic Left Heart Syndrome scheduled for Q3, investor attention is heightened despite expected earnings losses this quarter.
Longeveron has secured $15 million in funding to advance its laromestrocel therapy, boosting investor confidence. This funding, along with the projected potential of the therapy, has significantly increased LGVN's stock value, prompting a surge of over 74%.
